HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

AbstractBACKGROUND:
The prevalence of heart failure with preserved ejection fraction is increasing. The prognosis worsens with pulmonary hypertension and right ventricular (RV) failure development. We targeted pulmonary hypertension and RV burden with the phosphodiesterase-5 inhibitor sildenafil.
METHODS AND RESULTS:
Forty-four patients with heart failure with preserved ejection fraction (heart failure signs and symptoms, diastolic dysfunction, ejection fraction ≥50%, and pulmonary artery systolic pressure >40 mm Hg) were randomly assigned to placebo or sildenafil (50 mg thrice per day). At 6 months, there was no improvement with placebo, but sildenafil mediated significant improvements in mean pulmonary artery pressure (-42.0±13.0%) and RV function, as suggested by leftward shift of the RV Frank-Starling relationship, increased tricuspid annular systolic excursion (+69.0±19.0%) and ejection rate (+17.0±8.3%), and reduced right atrial pressure (-54.0±7.2%). These effects may have resulted from changes within the lung (reduced lung water content and improved alveolar-capillary gas conductance, +15.8±4.5%), the pulmonary vasculature (arteriolar resistance, -71.0±8.2%), and left-sided cardiac function (wedge pulmonary pressure, -15.7±3.1%; cardiac index, +6.0±0.9%; deceleration time, -13.0±1.9%; isovolumic relaxation time, -14.0±1.7%; septal mitral annulus velocity, -76.4±9.2%). Results were similar at 12 months.
CONCLUSIONS:
The multifaceted response to phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction includes improvement in pulmonary pressure and vasomotility, RV function and dimension, left ventricular relaxation and distensibility (structural changes and/or ventricular interdependence), and lung interstitial water metabolism (wedge pulmonary pressure decrease improving hydrostatic balance and right atrial pressure reduction facilitating lung lymphatic drainage). These results enhance our understanding of heart failure with preserved ejection fraction and offer new directions for therapy.
CLINICAL TRIAL REGISTRATION:
URL: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT01156636.
AuthorsMarco Guazzi, Marco Vicenzi, Ross Arena, Maurizio D Guazzi
JournalCirculation (Circulation) Vol. 124 Issue 2 Pg. 164-74 (Jul 12 2011) ISSN: 1524-4539 [Electronic] United States
PMID21709061 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Phosphodiesterase 5 Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Sildenafil Citrate
Topics
  • Aged
  • Aged, 80 and over
  • Double-Blind Method
  • Female
  • Heart Failure (complications, drug therapy, epidemiology, physiopathology)
  • Humans
  • Hypertension, Pulmonary (drug therapy, epidemiology, etiology, physiopathology)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors (administration & dosage)
  • Piperazines (administration & dosage)
  • Prevalence
  • Purines (administration & dosage)
  • Respiratory Function Tests (methods)
  • Sildenafil Citrate
  • Stroke Volume (drug effects)
  • Sulfones (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: